What does the MAKE composite include?

MAKE = death OR dialysis dependence at 90 days OR >=25% sustained reduction in eGFR from baseline. MAKE-90 is the most commonly used primary endpoint in AKI trials.

Why is MAKE used instead of mortality alone?

Mortality alone misses important kidney-specific outcomes. MAKE captures clinically meaningful outcomes (dialysis dependence, CKD progression) even when mortality differences are not significant.

Is MAKE used in non-research settings?

MAKE is primarily a research endpoint but guides risk stratification. Patients who survive AKI with 25% eGFR loss should receive nephrology follow-up within 90 days per KDIGO.

MAKE Major Adverse Kidney Events Composite

Calculate major adverse kidney events (MAKE) composite: death, dialysis dependence, or 25% sustained eGFR reduction from baseline, used as primary endpoint in AKI clinical trials.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.

How It Works

Calculate major adverse kidney events (MAKE) composite: death, dialysis dependence, or 25% sustained eGFR reduction from baseline, used as primary endpoint in AKI clinical trials

Each component has a specific meaning:

Baseline — The baseline recorded for the scenario being assessed.
Used as primary endpoint in AKI clinical trials — The used as primary endpoint in aki clinical trials recorded for the scenario being assessed.

Note: Interpret the make composite endpoint result against the thresholds and context described above.

How to Use

Enter the baseline, used as primary endpoint in AKI clinical trials for the scenario you are assessing. Calculate major adverse kidney events (MAKE) composite: death, dialysis dependence, or 25% sustained eGFR reduction from baseline, used as primary endpoint in AKI clinical trials. Use the make composite endpoint result to inform your calculation.

Related Calculators

RRT Timing Strategy

Hyper-niche Medical

AKI to CKD Transition Risk